Biology subjects

Hansson, O.

Publications and source records attributed to Hansson, O..

27 records · Page 2Linked to original sources

bioRxiv2020

Medial temporal atrophy in preclinical dementia: visual and automated assessment during six year follow-up

AO_SCPLOWBSTRACTC_SCPLOWMedial temporal lobe (MTL) atrophy is an important morphological marker of many dementias and is closely related to cognitive decline. In this study we aimed to characterize longitudinal progression of MTL atrophy in 93 individuals with subjective cognitive decline and mild cognitive impairment followed up over six years, and to assess if clinical rating scales are able to detect these changes. All MRI images were visually rated according to Scheltens scale of medial temporal atrophy (MTA) by two neuroradiologists and AVRA, a software for automated MTA ratings. The images were also segmented using FreeSurfers longitudinal pipeline in order to compare the MTA ratings to volumes of the hippocampi and inferior lateral ventricles. We found that MTL atrophy rates increased with CSF biomarker abnormality, used to define preclinical stages of Alzheimers Disease. Both AVRAs and the radiologists MTA ratings showed a similar longitudinal trajectory as the subcortical volumes, suggesting that visual rating scales provide a valid alternative to automatic segmentations. While the MTA scores from each radiologist showed strong correlations to subcortical volumes, the inter-rater agreement was low. We conclude that the main limitation of quantifying MTL atrophy with visual ratings in clinics is the subjectiveness of the assessment.

neuroscience↗

bioRxiv2019

Kinetic fingerprint of antibody therapies predicts outcomes of Alzheimer clinical trials

The amyloid cascade hypothesis, according to which the self-assembly of amyloid-{beta} peptide (A{beta}) is a causative process in Alzheimers disease, has driven many therapeutic efforts for the past 20 years. Failures of clinical trials investigating A{beta}-targeted therapies have been interpreted as evidence against this hypothesis, irrespective of the characteristics and mechanisms of action of the therapeutic agents, which are highly challenging to assess. We bring together kinetic analysis with quantitative binding measurements to address the mechanisms of action of four clinical stage anti-A{beta} antibodies, aducanumab, gantenerumab, bapineuzumab and solanezumab. We reveal and quantify the striking differences of these antibodies on the aggregation kinetics and on the production of oligomeric aggregates, and link these effects to the affinity and stoichiometry of each antibody for monomeric and fibrillar forms of A{beta}. Our results uncover that, uniquely amongst these four antibodies, aducanumab dramatically reduces the flux of oligomeric forms of A{beta}.

biophysics↗

bioRxiv2019

Influence of genetic variants on gene expression in human pancreatic islets - implications for type 2 diabetes

Most signals detected by genome-wide association studies map to non-coding sequence and their tissue-specific effects influence transcriptional regulation. However, many key tissues and cell-types required for appropriate functional inference are absent from large-scale resources such as ENCODE and GTEx. We explored the relationship between genetic variants influencing predisposition to type 2 diabetes (T2D) and related glycemic traits, and human pancreatic islet transcription using RNA-Seq and genotyping data from 420 islet donors. We find: (a) eQTLs have a variable replication rate across the 44 GTEx tissues (<73%), indicating that our study captured islet-specific cis-eQTL signals; (b) islet eQTL signals show marked overlap with islet epigenome annotation, though eQTL effect size is reduced in the stretch enhancers most strongly implicated in GWAS signal location; (c) selective enrichment of islet eQTL overlap with the subset of T2D variants implicated in islet dysfunction; and (d) colocalization between islet eQTLs and variants influencing T2D or related glycemic traits, delivering candidate effector transcripts at 23 loci, including DGKB and TCF7L2. Our findings illustrate the advantages of performing functional and regulatory studies in tissues of greatest disease-relevance while expanding our mechanistic insights into complex traits association loci activity with an expanded list of putative transcripts implicated in T2D development.

genomics↗

bioRxiv2019

Pathological tau spreads through communicating brain regions in human Alzheimer's disease

Tau is one of the two pathological hallmarks of Alzheimers disease, and bears a much closer relationship to local neurodegeneration and cognitive impairment than the other hallmark, {beta}-amyloid. Cell and rodent models have shown evidence that tau spreads from cell to cell through anatomical neuronal connections, and that this process is facilitated by the presence of {beta}-amyloid. We test this hypothesis in humans by using an epidemic spreading model (ESM) to simulate the spread of tau over human neuronal connections, and we compare the simulated pattern of progression to the observed pattern measured in the brains of 312 individuals on the Alzheimers disease spectrum, using PET. Fitting our model, we found that the majority of variance in the overall pattern of tau progression could be explained by diffusion of an agent through the human connectome, measured using either functional connectivity or diffusion tractography. These models far exceeded chance, and outperformed models testing the extracellular spread of tau over Euclidian space. Surprisingly, the ESM predicted the spatial patterns of tau irrespective of whether subjects demonstrated evidence for brain {beta}-amyloid. In addition, in {beta}-amyloid-positive subjects only, regions with greater amyloid burden showed greater tau than predicted by connectivity patterns, suggesting a role of amyloid in accelerating the spread of tau in certain isocortical regions. Altogether, our results provide strong evidence that tau spreads through neuronal communication pathways even in normal aging, and that this process is accelerated by the presence of brain {beta}-amyloid.

neuroscience↗

bioRxiv2018

Loss of ZnT8 function protects against diabetes by enhanced insulin secretion

A rare loss-of-function variant p.Arg138* in SLC30A8 encoding the zinc transporter 8 (ZnT8) enriched in Western Finland protects against type 2 diabetes (T2D). We recruited relatives of the identified carriers and showed that protection was associated with better insulin secretion due to enhanced glucose responsiveness and proinsulin conversion, especially compared with individuals matched for the genotype of a common T2D risk variant in SLC30A8, p.Arg325. In genome-edited human IPS-derived {beta}-like cells, we establish that the p.Arg138* variant results in reduced SLC30A8 expression due to haploinsufficiency. In human {beta}-cells loss of SLC30A8 leads to increased glucose responsiveness and reduced KATP channel function, which was also seen in isolated islets from carriers of the T2D-protective allele p.Trp325. These data position ZnT8 as an appealing target for treatment aiming at maintaining insulin secretion capacity in T2D.

genetics↗

bioRxiv2018

Islet Gene View - a tool to facilitate islet research

Changes in the hormone-producing pancreatic islets are central culprits in type 2 diabetes (T2D) pathogenesis. Characterization of gene expression in islets how it is altered in T2D are therefore vital in understanding islet function and T2D pathogenesis. We leveraged RNA-sequencing and genome-wide genotyping in islets from 188 donors to create the Islet Gene View (IGW) platform to make this information easily accessible to the scientific community. The IGW combines expression data for a given gene with phenotypical data such as T2D status, BMI, HbA1c, insulin secretion, purity of islets, etc.), regulation of gene expression by genetic variants e.g., expression quantitative trait loci (eQTLs) and relationship with expression of islet hormones. In IGW, 285 differentially expressed genes (DEGs) were identified in T2D donors islets compared to controls. Forty percent of the DEGs showed cell-type enrichment and a large proportion of them were significantly co-expressed with islet hormone-encoding genes like glucagon (GCG, 56%), amylin (IAPP, 52%), insulin (INS, 44%) and somatostatin (SST, 24%). Inhibition of two DEGs, UNC5D and SERPINE2 impaired glucose-stimulated insulin secretion and impacted cell survival in a human beta-cell model. Significance StatementWe present Islet Gene View (IGW), a web resource facilitating information on gene expression in human pancreatic islets from organ donors easily accessible to the scientific community. In IGW, we explored RNA expression from 188 donor-islets and examined their relationship with islet phenotypes including insulin secretion and expression of genes encoding islet hormones. GWAS have shown 403 genetic variants associated with risk of type 2 diabetes (T2D) risk, however, the target genes and function of these variants in islets are largely unknown. By linking T2D risk variants to expression in islets from T2D and non-diabetic donors as well as islet phenotypes, use of IGW provided new insight into mechanisms by which variants in these loci may increase risk of T2D.

molecular biology↗

bioRxiv2018

Data-driven approaches improve Tau-PET biomarkers in Alzheimer’s disease

Previous positron emission tomography (PET) studies have quantified filamentous tau pathology using regions-of-interest (ROIs) based on observations of the topographical distribution of neurofibrillary tangles in post-mortem tissue. However, such approaches may not take full advantage of information contained in neuroimaging data. The present study employs an unsupervised data-driven method to identify spatial patterns of tau-PET distribution, and to compare these patterns to previously published \"pathology-driven\" ROIs. Tau-PET patterns were identified from a discovery sample comprised of 123 normal controls and patients with mild cognitive impairment or Alzheimers disease (AD) dementia from the Swedish BioFINDER cohort, who underwent [18F]AV1451 PET scanning. Associations with cognition were tested in a separate sample of 90 individuals from ADNI. BioFINDER [18F]AV1451 images were entered into a robust voxelwise stable clustering algorithm, which resulted in five clusters. Mean [18F]AV1451 uptake in the data-driven clusters, and in 35 previously published pathology-driven ROIs, was extracted from ADNI [18F]AV1451 scans. We performed linear models comparing [18F]AV1451 signal across all 40 ROIs to several tests of global cognition, adjusting for age, sex and education. Two data-driven ROIs consistently demonstrated the strongest or near-strongest effect sizes across all cognitive tests. Inputting all regions plus demographics into a feature selection routine resulted in selection of two ROIs (one data-driven, one pathology-driven) and education, which together explained 28% of the variance of a global cognitive composite score. Our findings suggest that [18F]AV1451-PET data naturally clusters into spatial patterns that are biologically meaningful and that may offer advantages as clinical tools.

neuroscience↗

bioRxiv2017

Inter-Chromosomal Linkage Reveals Errors in the 1000 Genomes Dataset

It is often unavoidable to combine data from different sequencing centers or sequencing platforms when compiling datasets with a large number of individuals. However, the different data are likely to contain specific systematic errors that will appear as SNPs. Here, we devise a method to detect systematic errors in combined datasets. To measure quality differences between individual genomes, we study pairs of variants that reside on different chromosomes and co-occur in individuals. The abundance of these pairs of variants in different genomes is then used to detect systematic errors due to batch effects. Applying our method to the 1000 Genomes dataset, we find that coding regions are enriched for errors, where about 1% of the higher-frequency variants are predicted to be erroneous, whereas errors outside of coding regions are much rarer (<0.001%). As expected, predicted errors are less often found than other variants in a dataset that was generated with a different sequencing technology, indicating that many of the candidates are indeed errors. However, predicted 1000 Genomes errors are also found in other large datasets; our observation is thus not specific to the 1000 Genomes dataset. Our results show that batch effects can be turned into a virtue by using the resulting variation in large scale datasets to detect systematic errors.

genomics↗

bioRxiv2017

Clustering of adult-onset diabetes into novel subgroups guides therapy and improves prediction of outcome

BackgroundDiabetes is presently classified into two main forms, type 1 (T1D) and type 2 diabetes (T2D), but especially T2D is highly heterogeneous. A refined classification could provide a powerful tool individualize treatment regimes and identify individuals with increased risk of complications already at diagnosis.\n\nMethodsWe applied data-driven cluster analysis (k-means and hierarchical clustering) in newly diagnosed diabetic patients (N=8,980) from the Swedish ANDIS (All New Diabetics in Scania) cohort, using five variables (GAD-antibodies, BMI, HbA1c, HOMA2-B and HOMA2-IR), and related to prospective data on development of complications and prescription of medication from patient records. Replication was performed in three independent cohorts: the Scania Diabetes Registry (SDR, N=1466), ANDIU (All New Diabetics in Uppsala, N=844) and DIREVA (Diabetes Registry Vaasa, N=3485). Cox regression and logistic regression was used to compare time to medication, time to reaching the treatment goal and risk of diabetic complications and genetic associations.\n\nFindingsWe identified 5 replicable clusters of diabetes patients, with significantly different patient characteristics and risk of diabetic complications. Particularly, individuals in the most insulin-resistant cluster 3 had significantly higher risk of diabetic kidney disease, but had been prescribed similar diabetes treatment compared to the less susceptible individuals in clusters 4 and 5. The insulin deficient cluster 2 had the highest risk of retinopathy. In support of the clustering, genetic associations to the clusters differed from those seen in traditional T2D.\n\nInterpretationWe could stratify patients into five subgroups predicting disease progression and development of diabetic complications more precisely than the current classification. This new substratificationn may help to tailor and target early treatment to patients who would benefit most, thereby representing a first step towards precision medicine in diabetes.\n\nFundingThe funders of the study had no role in study design, data collection, analysis, interpretation or writing of the report.\n\nResearch in contextEvidence before this study\n\nThe current diabetes classification into T1D and T2D relies primarily on presence (T1D) or absence (T2D) of autoantibodies against pancreatic islet beta cell autoantigens and age at diagnosis (earlier for T1D). With this approach 75-85% of patients are classified as T2D. A third subgroup, Latent Autoimmune Diabetes in Adults (LADA,<10%), is defined by presence of autoantibodies against glutamate decarboxylase (GADA) with onset in adult age. In addition, several rare monogenic forms of diabetes have been described, including Maturity Onset Diabetes of the Young (MODY) and neonatal diabetes. This information is provided by national guidelines (ADA,WHO, IDF, Diabetes UK etc) but has not been much updated during the past 20 years and very few attempts have been made to explore heterogeneity of T2D. A topological analysis of potential T2D subgroups using electronic health records was published in 2015 but this information has not been implemented in the clinic.\n\nAdded value of this study\n\nHere we applied a data-driven cluster analysis of 5 simple variables measured at diagnosis in 4 independent cohorts of newly-diagnosed diabetic patients (N=14755) and identified 5 replicable clusters of diabetes patients, with significantly different patient characteristics and risk of diabetic complications. Particularly, individuals in the most insulin-resistant cluster 3 had significantly higher risk of diabetic kidney disease.\n\nImplications of the available evidence\n\nThis new sub-stratification may help to tailor and target early treatment to patients who would benefit most, thereby representing a first step towards precision medicine in diabetes

epidemiology↗